Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Withdrawn 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 1Thoracic 1

Conditions

Lymphoma, T-Cell, Peripheral 7Ovarian Neoplasms 6Lymphoma, Non-Hodgkin 6Lymphoma, Large B-Cell, Diffuse 6Lymphoma 6Leukemia, Myeloid, Acute 6Lymphoma, T-Cell, Cutaneous 5Carcinoma, Non-Small-Cell Lung 5Breast Neoplasms 5Recurrence 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Lymphoma, T-Cell 4Lymphoma, Mantle-Cell 4Lymphoma, Large-Cell, Anaplastic 4Lymphoma, Follicular 4Lymphoma, B-Cell, Marginal Zone 4Lung Neoplasms 4Hodgkin Disease 4Hematologic Neoplasms 4Waldenstrom Macroglobulinemia 3Urinary Bladder Neoplasms 3Sarcoma 3Neoplasms 3Myelodysplastic Syndromes 3Mycosis Fungoides 3Leukemia, Myelogenous, Chronic, BCR-ABL Positive 3Immunoblastic Lymphadenopathy 3Fallopian Tube Neoplasms 3Burkitt Lymphoma 3Thyroid Neoplasms 2

Interventions

Oxaliplatin 46Gemcitabine 45Fluorouracil 40Capecitabine 31pembrolizumab 30Leucovorin 29Docetaxel 27Cisplatin 25Paclitaxel 23Irinotecan 18Carboplatin 18Bevacizumab 18130-nm albumin-bound paclitaxel 17Radiotherapy 16Pemetrexed 15Albumin-Bound Paclitaxel 15Nivolumab 13Ramucirumab 11Cyclophosphamide 11Drug Therapy 9Trastuzumab 8Erlotinib Hydrochloride 8zolbetuximab 7Taxes 7Radiosurgery 7trastuzumab deruxtecan 6cemiplimab 6Blood Specimen Collection 6regorafenib 5durvalumab 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Adenocarcinoma × belinostat × Clear all
NCT04315155 2020-10-28

BENEFIT

University of Utah

Phase 1 Withdrawn
Tumor-Agnostic

Adenocarcinoma

NCT01310244 2020-01-06

MTD Study PXD-101 in Combination With Paclitaxel + Carboplatin in Chemotherapy-Naive Patients With Stage IV NSCLC

Acrotech Biopharma Inc.

Phase 1/2 Completed
23 enrolled
Thoracic

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡